Souhaitez-vous accéder aux communiqués récents ?

BOTHELL, Wash., April 21, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high...

Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc....

VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) announces HealthTab™ has now screened more than 3,500 patients in...

BudPop's Delta-9 + CBN Sleep Gummies ranked #1 of 47 brands tested. 98% batch consistency, 2.1% potency variance. Research-backed cannabinoid sleep aid.

BudPop Delta-9 + CBN Gummies featured in 2026 analysis of cannabinoid sleep formulations. Independent review examines 47 products.

Dr. Bruce Lahn’s team at VectorBuilder developed Potency-Seq, revealing how genes lose activation potential during cell differentiation.

ICP-B794 demonstrated potent anti-tumor activity in preclinical tumor models and a significantly larger safety window compared to similar drugs.

Hyalex Orthopaedics Announces FDA 510(k) Clearance of the HYALEX Slalom™ MTP Hemiarthroplasty System

Xeltis announces that it has received CE mark for aXess™

Groundbreaking approaches such as cell therapies are on the horizon for transformation of neural hearing loss, a widespread but underdiagnosed condition.